Filing Flows › NewAmsterdam Pharma Co N.V. (NAMS) › Q3 2026 › vs Q3 2025
NewAmsterdam Pharma Co N.V. (NAMS) Q3 2026 vs Q3 2025 (year over year)
NewAmsterdam Pharma Co N.V.'s revenue rose $18.8M (55×) from $348K in Q3 2025 to $19.2M in Q3 2026.
NewAmsterdam Pharma Co N.V., Q3 2026: revenue $19.2M (55× year over year), operating margin -230.6%, net loss $17.4M, operating cash flow −$39.8M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $19.2M | $348K | $18.8M | 55× |
| Other income, net | $28.0M | −$16.9M | $44.9M | — |
| Net loss | $17.4M | $72.0M | −$54.6M | -76% |
| Costs & expenses | $64.6M | $72.4M | −$7.8M | -11% |
| Operating costs | $63.4M | $55.5M | $7.9M | +14% |
| Income tax | $1.2M | $0 | $1.2M | — |
| Research & development | $39.4M | $31.0M | $8.4M | +27% |
| SG&A | $24.0M | $24.5M | −$526K | -2% |
| Operating cash sources | $52.4M | $47.8M | $4.5M | +9% |
| Depreciation & amortization | $67K | $64K | $3K | +5% |
| Share-based compensation | $12.5M | $15.0M | −$2.5M | -17% |
| Cash used in operations | $39.8M | $32.8M | $7.0M | +21% |
| Net loss absorbed | $17.4M | $72.0M | −$54.6M | -76% |
| Working capital & other | $35.0M | −$24.2M | $59.1M | — |
Questions
How much did NewAmsterdam Pharma Co N.V.'s revenue grow year over year in Q3 2026?
NewAmsterdam Pharma Co N.V.'s revenue rose $18.8M (55×) from $348K in Q3 2025 to $19.2M in Q3 2026.